Alipogene tiparvovec

From Infogalactic: the planetary knowledge core
(Redirected from Glybera)
Jump to: navigation, search
Alipogene tiparvovec
Clinical data
Trade names Glybera
AHFS/Drugs.com UK Drug Information
Legal status
  • ℞ (Prescription only)
Routes of
administration		 Intramuscular injection
Identifiers
CAS Number 929881-05-0
ATC code C10AX10 (WHO)
UNII 20OK4AFR4Y YesY
File:AAV Gene Therapy.jpg
Gene therapy using an AAV vector. A new gene is inserted into a cell using the AAV protein shell. Once inside the nucleus, the new gene makes functional protein to treat a disease.

Alipogene tiparvovec (marketed under the trade name Glybera) is a gene therapy treatment that compensates for lipoprotein lipase deficiency (LPLD), a rare inherited disorder which can cause severe pancreatitis.[1] In July 2012, the European Medicines Agency recommended it for approval, the first recommendation for a gene therapy treatment in either Europe or the United States. The recommendation was endorsed by the European Commission in November 2012[2][3]

Mechanism

The adeno-associated virus serotype 1 (AAV1) viral vector delivers an intact copy of the human lipoprotein lipase (LPL) gene to muscle cells. The LPL gene is not inserted into the cell's chromosomes but remains as free floating DNA in the nucleus. The injection is followed by immunosuppressive therapy to prevent immune reactions to the virus.[4]

Data from the clinical trials indicates that fat concentrations in blood were reduced between 3 and 12 weeks after injection, in nearly all patients. The advantages of AAV include apparent lack of pathogenicity, delivery to non-dividing cells, and much smaller risk of insertion[5] compared to retroviruses, which show random insertion with accompanying risk of cancer. AAV also presents very low immunogenicity, mainly restricted to generating neutralizing antibodies, and little well defined cytotoxic response.[6][7][8] The cloning capacity of the vector is limited to replacement of the virus's 4.8 kilobase genome.

Development

Trials

LPLD is a very rare condition (prevalence worldwide 1–2 per million) and as such its clinical testing has involved unusually small cohort sizes. The first main trial (CT-AMT-010-01) involved just 14 subjects[9] and as of 2015 a total 27 individual individuals have been involved in Phase III testing.[10]

Cost

Alipogene tiparvovec was expected to cost around $1.6 million per treatment in 2012,[11] revised to $1 million in 2015,[12] making it the most expensive medicine in the world at the time.[13]

See Also

References

  1. ↑ European Agency Backs Approval of a Gene Therapy July 20, 2012
  2. ↑ Gallagher, James. (2012-11-02) BBC News – Gene therapy: Glybera approved by European Commission. Bbc.co.uk. Retrieved on 2012-12-15.
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  4. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  5. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  6. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  7. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  8. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  9. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  10. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  11. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  12. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  13. ↑ Gene therapy approved in Europe for first time
Retrieved from "https://infogalactic.com/w/index.php?title=Alipogene_tiparvovec&oldid=721604665"